NEUROMARK® Expands Access Through UnitedHealthcare's Medicare Advantage Policy Changes
NEUROMARK® Expands Access Through UnitedHealthcare's Medicare Advantage Policy Changes
Neurent Medical, a pioneering name in non-surgical treatments for chronic rhinitis, has announced a significant update regarding the accessibility of its NEUROMARK® system. Effective immediately, UnitedHealthcare's Medicare Advantage has reclassified CPT 31242, which pertains to the posterior nasal nerve ablation using radiofrequency energy, removing it from the Experimental Investigational (EI) list. This monumental change now grants over 10 million Medicare Advantage patients access to NEUROMARK.
The policy update reflects a growing recognition among payers regarding the effectiveness and therapeutic value of modern treatments for chronic rhinitis. Notably, this update follows a similar announcement from Cigna earlier in September, which underscores a significant trend towards improving patient access to innovative treatment solutions.
Previously, the classification as experimental posed a substantial barrier for Ear, Nose, and Throat (ENT) specialists, limiting their ability to offer this particular treatment to patients enrolled in UnitedHealthcare's plans. But with this policy change, practitioners are now in a better position to provide evidence-based care and help patients alleviate their chronic rhinitis symptoms.
"UnitedHealthcare's Medicare Advantage's policy change is another validation of the clinical need for modern, minimally invasive treatment options," remarked Brian Shields, CEO of Neurent Medical. He emphasized the company's commitment to collaborating with payers and healthcare providers to ensure patients living with chronic rhinitis can access effective solutions and reduce their reliance on long-term medications.
The NEUROMARK® System
The NEUROMARK System utilizes impedance-controlled, low-power radiofrequency energy to disrupt aberrant parasympathetic nerve signals. This intervention specifically targets symptoms associated with chronic rhinitis, including persistent nasal congestion and rhinorrhea (runny nose). The technology is designed to enhance the quality of life for patients, making it a vital tool in contemporary ENT practice.
Dr. Marc Dubin, a prominent ENT specialist, emphasized the importance of this policy shift: "By removing unnecessary administrative barriers, ENTs are better positioned to deliver evidence-based care that finally helps patients find relief from chronic rhinitis symptoms."
Key Points for Healthcare Providers
- - CPT 31242 is officially reclassified: UnitedHealthcare no longer considers this procedure investigational, streamlining access to NEUROMARK for eligible patients.
- - Improved access: The updated policy supports a quicker and more efficient process for patients seeking the NEUROMARK treatment option.
For healthcare providers wishing to learn more, UnitedHealthcare's updated medical policy can be found here.
About Neurent Medical
Neurent Medical is at the forefront of addressing chronic inflammatory sinonasal diseases through non-invasive treatments. The NEUROMARK technology is specifically aimed at disrupting hyperactive autonomic nerves that contribute to inflammation. With a unique design and smart algorithm, it allows healthcare professionals to target multiple nerve branches effectively within a single procedure, culminating in better patient outcomes. The company operates out of Galway, Ireland, and boasts a U.S. headquarters in Braintree, Massachusetts. For further information, visit www.neuromark.com.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.